Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in ...
First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane ...
Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...
The trial is the first to test a bispecific monoclonal antibody as early as the first relapse after initial treatment for multiple myeloma. Based on the findings, researchers suggest the combination ...
ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results